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SCIENTIFIC OPINION 
Statement on the safety of the “conjugated linoleic acid (CLA)-rich oils” 
Clarinol
® 
and Tonalin  TG 80 as Novel Food ingredients
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies was 
asked to update its opinions on the safety of the conjugated linoleic acid (CLA)-rich oils Clarinol® and Tonalin  
TG 80 as Novel Food ingredients in the light of additional information provided by Member States to the 
European Commission. Clarinol® and Tonalin  TG 80 consist of approximately 80 % of the two CLA isomers 
c-9,t-11 and t-10,c-12 (1:1). The applicants suggested a daily intake of CLA of 3 g (3.75 g Clarinol®) and 3.5 g 
(4.5 g Tonalin  TG 80), respectively. The Panel considers that the additional information provided does not 
contain evidence thath would modify its previous conclusions regarding the effects of CLA on insulin 
sensitivity/glucose metabolism, blood lipids, lipid peroxidation, or subclinical inflammation. The Panel also 
considers that the new studies provided do not address longer-term (> 6 months) effects of CLA intake on insulin 
sensitivity, the arterial wall or liver steatosis, or the safety of CLA in type-2 diabetic subjects, under the proposed 
conditions of use. The Panel concludes that the safety of Clarinol® and Tonalin  TG 80 has been established for 
the proposed uses and daily doses for up to six months. The safety of CLA consumption for periods longer than 
six months has not been established under the proposed conditions of use. The safety of CLA consumption by 
type-2 diabetic subjects has not been established.  
© European Food Safety Authority, 2012 
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SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to update its opinions on the safety of the conjugated linoleic acid (CLA)-rich 
oils Clarinol® and Tonalin  TG 80 as Novel Food ingredients in the light of additional information 
provided by Member States to the European Commission. 
Clarinol® and Tonalin  TG 80 consist of approximately 80 % of the two CLA isomers c-9,t-11 and 
t-10,c-12 (1:1). Clarinol® and Tonalin  TG 80 were intended by the applicants as ingredients in 
beverages, cereal products, dietary supplements, and milk products for adult consumers. The 
applicants suggested a daily intake of 3 g CLA, corresponding to approximately 3.75 g Clarinol®, and 
of 3.5 g, corresponding to approximately 4.5 g Tonalin  TG 80, respectively.  
In its previous opinions, the Panel considered that CLA consumption did not appear to have adverse 
effects on insulin sensitivity, blood glucose control or liver function for periods up to six months, and 
that the observed effects on blood lipids were unlikely to have an impact on cardiovascular disease 
risk. However, the observed increase in plasma and urinary concentrations of isoprostanes, which may 
indicate an increase in lipid peroxidation, and the increase in some markers of subclinical 
inflammation (i.e., 15-keto-dihydroprostaglandin F2  and possibly CRP) associated with CLA 
consumption, together with the limited data available on the effects of CLA on vascular function, may 
indicate a potential for vascular damage (i.e., atherosclerosis) in the long term. Long-term effects of 
CLA intake on insulin sensitivity, the arterial wall or liver steatosis had not been adequately 
addressed in humans. The evidence provided did not establish the safety of CLA consumption by 
type-2 diabetic subjects under the proposed conditions of use. 
The Panel considers that the additional information provided does not contain evidence that would 
modify the previous conclusions reached by the Panel regarding the effects of CLA on insulin 
sensitivity, blood glucose control, blood lipids, lipid peroxidation, or subclinical inflammation. The 
Panel also considers that the new studies provided do not address longer-term (> 6 months) effects of 
CLA intake on insulin sensitivity, the arterial wall or liver steatosis, or the safety of CLA in type-2 
diabetic subjects, under the proposed conditions of use.    
The Panel concludes that the safety of Clarinol® and Tonalin  TG 80 has been established for the 
proposed uses and daily doses (3.75 g Clarinol® and 4.5 g Tonalin  TG 80 corresponding to 
approximately 3 and 3.5 g of CLA, respectively) for up to six months. The safety of CLA 
consumption for periods longer than six months has not been established under the proposed 
conditions of use. The safety of CLA consumption by type-2 diabetic subjects has not been 
established.  
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
On 30 April 2010, EFSA adopted two Scientific Opinions on the safety of “conjugated linoleic acid 
(CLA)-rich oil” as a novel food ingredient 4,5. 
The conclusion of the EFSA opinions was that the safety of CLA consumption for more than six 
months has not been established. Subsequently member States could not support a Commission 
Decision authorising the use of CLA as a novel food ingredient. Instead member States provided 
additional information that was considered to be relevant for the safety assessment.  
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
In view of the above the Commission requests EFSA to review and update its opinions in the light of 
the following additional information: 
1. Effect of animal and industrial trans fatty acids on HDL and LDL cholesterol levels in humans-a 
quantitative review. Browers et al. (2010) PLoS ONE, March 2010, Volume 5, Issue 3, e9434. 
2. Effect of a high intake of conjugated linoleic acid on lipoprotein levels in healthy human subjects. 
Wanders et al (2010) PLoS ONE, February 2010, Volume 5, Issue 2, e9000. 
3. Application A1005. Exclusive use of Tonalin  CLA as a novel food assessment report, 13 May 
2011, Food Standards Australia and New Zealand (FSANZ).  
4. Publication of the Superior Health Council No. 8736. Novel food ingredients: oils rich in 
conjugated linoleic acid in food, 6 July 2011.  
5. Opinion of the French Agency for Food, Environmental and Occupational Health & Safety 
(ANSES) on a “safety assessment of the use of an oil enriched with Conjugated Linoleic Acid 
(CLA)”. 7 October 2011. Request no. 2011-SA-0185 
                                                     
 
4 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the safety of “conjugated linoleic 
acid (CLA)-rich oil” (Cognis) as a Novel Food ingredient. EFSA Journal 2010; 8(5):1600 [43 pp.]. 
doi:10.2903/j.efsa.2010.1600.  
5 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the safety of “conjugated linoleic 
acid (CLA)-rich oil” (Lipid Nutrition) as a Novel Food ingredient. EFSA Journal 2010; 8(5):1601 [41 pp.]. 
doi:10.2903/j.efsa.2010.1601.  
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EVALUATION 
1. Introduction 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to carry out the additional assessment for Clarinol® and Tonalin  TG 80, two 
conjugated linoleic acid (CLA)-rich oils, as novel food ingredients in the context of Regulation (EC) 
No. 258/97. Clarinol® and Tonalin  TG 80 consist of approximately 80 % of the two CLA isomers 
c-9,t-11 and t-10,c-12 (1:1). Clarinol® and Tonalin  TG 80 were intended by the applicants as 
ingredients in beverages, cereal products, dietary supplements, and milk products for adult consumers. 
The applicants suggested a daily intake of 3 g CLA, corresponding to approximately 3.75 g 
Clarinol®, and of 3.5 g, corresponding to approximately 4.5 g Tonalin  TG 80, respectively.  
The Panel concluded that the safety of Clarinol® and Tonalin  TG 80 had been established for the 
proposed uses and levels of intake for up to six months, that the safety of CLA consumption for 
periods longer than six months had not been established under the proposed conditions of use, and 
that the safety of CLA consumption by type-2 diabetic subjects had not been established. 
These conclusions were based on the following considerations:  
1. The administration of CLA to normal weight, overweight and obese non-diabetic subjects did not 
appear to have adverse effects on insulin sensitivity, blood glucose control or liver function at the 
proposed conditions of use for up to six months. 
2. The effects of CLA consumption over periods longer than six months on insulin sensitivity and 
liver steatosis had not been adequately addressed in humans. 
3. CLA appeared to adversely affect both static and dynamic surrogate markers of insulin sensitivity 
as well as fasting blood glucose concentrations in subjects with type-2 diabetes and no studies on 
blood glucose control (e.g., HbA1c) were available for periods of consumption beyond eight weeks in 
this population subgroup.  
4. Under the proposed conditions of use, CLA was considered to have no effect on LDL-cholesterol 
concentrations or the LDL:HDL-cholesterol ratio, and the magnitude of the changes observed in 
HDL- and triglyceride concentrations were unlikely to have an impact on CVD risk.  
5. The observed increase in plasma and urinary concentrations of isoprostanes, which may indicate an 
increase in lipid peroxidation, and the increase in some markers of subclinical inflammation 
(i.e., 15-keto-dihydroprostaglandin F2  and possibly CRP) associated with CLA consumption, together 
with the limited data available on the effects of CLA on vascular function, were considered to indicate 
a potential for vascular damage (i.e., atherosclerosis) in the longer term, and no data on effects of 
CLA intake on the arterial wall had been provided in humans. 
2. Additional information provided  
In the context of the present opinion, the three reports from National Authorities provided in the 
Terms of Reference (ToR) will be considered as sources of information that may not have been taken 
into account in previous evaluations (EFSA 2010a and b). In this respect, in vitro and animal studies 
showing an effect of CLA isomers, and in particular of the t-10,c-12 CLA isomer, on glucose uptake, 
insulin sensitivity or blood glucose control were considered to identify critical outcomes in relation to 
glucose homeostasis for the safety assessment of CLA isomers in human intervention studies, which 
were the basis for the conclusions of the NDA Panel. The Panel considers that recently published in 
Safety of “conjugated linoleic acid (CLA)-rich oils” 
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vitro and animal studies that have assessed the effects of CLA on e.g., measures of glucose uptake or 
insulin sensitivity (Halade et al., 2010; Hommelberg et al., 2010; Kennedy et al., 2009; 2010a) do not 
provide additional information about the safety of CLA consumption in humans. 
3. Effects of CLA consumption in humans 
Among the additional human studies identified in the opinion by the French Agency for Food, 
Environmental and Occupational Health and Safety (ANSES, 2011) as not being considered by EFSA 
(EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2010a, 2010b), the Panel considers 
that only human intervention studies testing the effects of CLA vs. a control fat may allow 
conclusions to be drawn on the safety of CLA. Therefore, case control studies reporting on CLA 
content in adipose tissue rather than on CLA intakes (Smit et al., 2010), one-arm studies without a 
control group (Thrush et al., 2007), studies using dairy products high or low in ruminant-derived 
mixes containing trans-vaccenic acid and the c-9,t-11 isomer of CLA (Brown et al., 2011; Desroches 
et al., 2005; Sofi et al., 2010; Tricon et al., 2006), studies giving CLA in milk or yoghurt drinks 
without replacing CLA with fat in the placebo vehicle (Bonet Serra et al., 2008), and studies in which 
CLA was given in conjunction with other potentially active ingredients without a CLA arm only for 
comparison (Ahren et al., 2009), have not been considered as sources of data for this evaluation.  
3.1. Effects on insulin sensitivity and glucose metabolism 
Since publication of the EFSA opinions, four additional randomised controlled trials (RCTs) in 
humans have been reported on the effects of CLA on fasting blood glucose and insulin concentrations 
and on the static surrogate marker of insulin resistance HOMA-IR (Joseph et al., 2011; Pfeuffer et al., 
2011; Racine et al., 2010; Sluijs et al., 2010). None of these studies had insulin sensitivity or glucose 
homeostasis as a primary outcome, but rather body weight and body composition (Joseph et al., 2011; 
Racine et al., 2010), aortic pulse wave velocity (PWV, Sluijs et al., 2010), or endothelial function 
(Pfeuffer et al., 2011). 
In the study by Racine et al. (2010) 62 overweight or obese pre-pubertal children aged 6-10 years 
were randomised to consume 2.4 g/day of CLA (50:50 mixture of the c-9, t-11 and t10,c-12 isomers) 
or a control fat (sunflower oil) in milk chocolate for 6 months. The study by Sluijs et al. (2010) was 
conducted in 401 overweight or obese adults (342 analysed) aged 40–70 years, randomised to receive 
3.1 g/day CLA (80:20 mixture of the c-9, t-11 and t10,c-12 isomers) or a control fat (a blend of 80 % 
palm oil and 20 % soybean oil) in capsules for 6 months. In the study by Pfeuffer et al. (2011), 85 
overweight men aged 45–68 years were randomized to receive 4.5 g/day of the 50:50 CLA isomeric 
mixture (3.6 g/day CLA), safflower oil, heated safflower oil, or olive oil for four weeks. The study by 
Joseph et al. (2011) was a 3-phase crossover trial conducted in 27 overweight males aged 18-60 years. 
Participants consumed in random order 3.5 g/day of safflower oil (control), of a 50:50 CLA isomeric 
mixture (2.8 g/day of CLA) and the CLA c-9, t-11 isomer (2.7 g/day CLA) for eight weeks each with 
a 4-week washout in between. No significant differences between the CLA and control groups on 
changes in fasting blood glucose or insulin concentrations, or in the HOMA-IR when calculated 
(Joseph et al., 2011; Pfeuffer et al., 2011; Sluijs et al., 2010), were reported in these studies. With the 
exception of the Pfeuffer et al. (2011) study, where body weight was reported to significantly 
decrease in the CLA group compared to all three control fats, body weight changes did not differ 
between the CLA and control groups. 
In the study by Pfeuffer et al. (2011), the glucose and insulin areas under the curve calculated from 
values at different time points for five hours after consumption of a standardised meal did not differ 
significantly between the CLA and control groups. 
The Panel notes that all these studies administered CLA for  6 months, were conducted in 
overweight or obese (and presumably non-diabetic) subjects, did not report on adequate measures of 
Safety of “conjugated linoleic acid (CLA)-rich oils” 
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insulin sensitivity or blood glucose control and were not powered on this basis. The Panel also notes 
that no new studies are available in type-2 diabetic subjects. 
The Panel considers that the additional information provided does not contain evidence that would 
modify the previous conclusions reached by the Panel regarding the effects of CLA on insulin 
sensitivity and glucose metabolism.  
3.2. Effects on blood lipids and lipoproteins 
Previous conclusions on the effects of CLA on the blood lipid profile (EFSA Panel on Dietetic 
Products Nutrition and Allergies (NDA), 2010a, 2010b) were based on two meta-analyses provided 
by the applicant (Clifton, 2009; Herrmann, 2009), which already considered the results from the study 
by Wanders et al., (2010a) cited in the ToR as additional information. In these meta-analyses, no 
significant effect of CLA consumption was observed on LDL-cholesterol concentrations or the 
LDL:HDL-cholesterol ratio compared to control fats. Blood HDL-cholesterol concentrations were 
reduced significantly in the CLA intervention group (by 5-6 %) compared to placebo (usually olive oil 
or safflower oil rich in oleic acid) in the meta-analysis by Clifton (2009) and in the meta-analysis by 
Hermann (2009) when only the eight studies using olive oil as placebo were considered. Blood 
concentrations of triglycerides were also significantly higher in the CLA group compared to placebo 
in the overall population, in subjects with a BMI >27 kg/m
2
, and in the studies using olive oil as 
placebo in this meta-analysis (Herrmann, 2009). The Panel noted that a significant (although modest) 
HDL-cholesterol lowering effect and a significant (although modest) triglyceride raising effect of the 
50:50 CLA isomeric mixture could not be excluded, which supported the notion that long-term 
changes in insulin sensitivity and associated changes in blood lipids may be associated with the 
chronic administration of CLA. The Panel considered that the magnitude of the changes observed in 
HDL- and triglyceride concentrations was unlikely to have an impact on coronary heart disease risk.  
In the assessment report by the Food Standards Australia and New Zealand (FSANZ, 2011) on the use 
of Tonalin  CLA as a novel food, a new meta-analysis conducted by FSANZ evaluated the effects of 
CLA on LDL and HDL-cholesterol concentrations. The effects on blood concentrations of 
triglycerides were not assessed. The meta-analysis by FSANZ was different from one of the 
meta-analyses provided by the applicant (Clifton, 2009) in that it excluded studies that used a 
ruminant-derived mix containing trans-vaccenic acid and the c-9,t-11 isomer of CLA (Desroches et 
al., 2005; Tricon et al., 2006), studies that used lactose as placebo (Yonei et al., 2007), and studies in 
which CLA was provided in milk or yoghurt drinks without replacing CLA with a fat as the placebo 
vehicle (Laso et al., 2007; López-Román et al., 2007). However, it included six additional studies 
(Aryaeian et al., 2009; Attar-Bashi et al., 2007; Herrmann, 2009; Park and Pariza, 2008; Sluijs et al., 
2010; Zhao et al., 2009), some of which were unavailable at the time the Clifton (2009) meta-analysis 
was submitted. 
Despite these differences in the selection of the studies and other differences regarding the 
methodology used for data analysis, the meta-analysis by FSANZ found a significant decrease in 
HDL-cholesterol concentrations which was half the size (2-3%) of that reported by Clifton (2009) and 
no significant changes in LDL-cholesterol concentrations during consumption of the 50:50 CLA 
mixture compared to control fats, some of which (e.g., cis-polyunsaturated fatty acids) are known to 
decrease LDL-cholesterol concentrations relative to isocaloric amounts of  carbohydrates (Mensink et 
al., 2003).   
The meta-analysis by Brouwer et al. (2010) provided in the ToR, that was designed to investigate the 
effects of animal and industrial trans fatty acids on LDL and HDL-cholesterol concentrations, 
evaluated 23 RCTs, 13 of which addressed the effects of CLA given as the 80:20 isomeric mixture of 
the c-9, t-11 and t10,c-12 isomers (n=3), as either isomer alone (n=1), or as the 50:50 isomeric 
mixture (n=9). The Panel notes that all these studies had  already been considered in the 
Safety of “conjugated linoleic acid (CLA)-rich oils” 
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meta-analyses discussed above (Clifton, 2009; FSANZ, 2011). The Panel also notes that the potential 
sources of bias in the meta-analysis by Brouwer et al. (2010), already outlined in the opinion by 
ANSES (2011), do not allow conclusions to be drawn on the effects of CLA on blood lipids in 
humans.   
The ANSES opinion (2011) also identified three recent reports on the effects of CLA on blood lipids 
that had not been included in the meta-analyses quoted above (Joseph et al., 2011; Pfeuffer et al., 
2011; Venkatramanan et al., 2010). Two of them had a cross-over design, included 15 
(Venkatramanan et al., 2010) and 36 (Joseph et al., 2011) overweight subjects, respectively, and 
provided CLA (as the c-9,t-11 isomer or the 50:50 isomer mixture) at doses up to 2.8 g/day for 8 
weeks. The third study had a parallel design, included about 20 overweight men per study arm, lasted 
4 weeks and used the 1:1 CLA isomer mixture at a dose of 3.6 g/day (Pfeuffer et al., 2011). No effect 
of CLA on blood lipids was observed in any of these studies. Pfeuffer et al. (2011) also reported no 
effect of CLA on lipoprotein (a). 
The Panel considers that the additional information provided does not contain evidence that would 
modify the previous conclusions reached by the Panel regarding the effects of CLA on blood lipids 
and lipoproteins.  
3.3. Markers of lipid peroxidation and oxidative stress 
The ANSES opinion (2011) identified four human intervention studies (Joseph et al., 2011; Pfeuffer 
et al., 2011; Smit et al., 2011; Turpeinen et al., 2008) on the effects of CLA on markers of lipid 
peroxidation that were not cited in previous EFSA opinions (EFSA Panel on Dietetic Products 
Nutrition and Allergies (NDA), 2010a, 2010b). Three of these reported on urinary excretion (Smit et 
al., 2011; Turpeinen et al., 2008) or plasma concentrations(Pfeuffer et al., 2011) of F2α isoprostanes, 
whereas two reported on plasma concentrations of oxidised LDL (Joseph et al., 2011; Pfeuffer et al., 
2011). One study (Kim et al., 2011) investigated the effects of CLA on other markers traditionally 
used to assess oxidative stress (TRAP, antioxidant enzymes, antioxidant vitamins). The Panel notes 
that changes in these markers do not indicate oxidative damage to molecules.   
The study by Pfeuffer et al. (2011) had a parallel design, was conducted in overweight males, 
administered the 50:50 CLA isomeric mixture (3.6 g/day) for four weeks and used safflower oil as 
control. In the study by Turpeinen et al. (2008), 40 subjects with pollen allergy were randomised to 
consume 2 g CLA/day (an 80:20 mixture of the c-9-t-11 and t-10-c-12 isomers) or high-oleic acid 
sunflower-seed oil for 12 weeks. The study by Smit et al. (2011) was a cross-over study in which 
61 adults described as healthy consumed three diets containing 7 % of the energy (about 20 g/day) as 
oleic acid (control), industrial trans fatty acids, or CLA (an 80:20 mixture of the c-9-t-11 and 
t-10-c-12 isomers) for three consecutive weeks each with no washout in between. Outcome variables 
were assessed at the end of each 3-week period. The Panel notes the limitations of this cross-over 
design and that CLA intakes were notably higher than those proposed for CLA as a novel food 
ingredient by the applicants.  
All these studies reported a significant increase in urinary excretion (Smit et al., 2011; Turpeinen et 
al., 2008) or plasma concentrations (Pfeuffer et al., 2011) of 8-iso-PGF2α, as well as an increase in the 
urinary excretion of 15-keto-dihydro-PGF2α (Turpeinen et al., 2008) with consumption of CLA 
compared to the control fat. No effect of CLA on plasma concentrations of oxidised LDL particles 
was reported in the two studies that addressed this outcome (Joseph et al., 2011; Pfeuffer et al., 2011).  
An additional study (Kim et al., 2011) investigated the effects of CLA (1.8 g/day, 50:50 isomer 
mixture) given for eight weeks on the total antioxidant capacity of plasma and on plasma 
concentrations of antioxidant enzymes and antioxidant vitamins. No effect of CLA was reported on 
any of these variables relative to olive oil.   
Safety of “conjugated linoleic acid (CLA)-rich oils” 
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The Panel notes that the results of these studies are in line with the consistent increase in plasma and 
urinary concentrations of F2-isoprostanes reported in previous publications (EFSA Panel on Dietetic 
Products Nutrition and Allergies (NDA), 2010a, 2010b) and that, therefore, the additional information 
provided by these studies does not modify the conclusions reached by the Panel regarding the effects 
of CLA on lipid peroxidation.  
3.4. Markers of systemic (subclinical) inflammation  
The ANSES opinion (2011) identified nine human intervention studies on the effects of CLA on 
markers of subclinical systemic inflammation [high-sensitivity C-reactive protein (hs-CRP), tumor 
necrosis factor  (TNF- ), interleukin-6 (IL-6), IL-5, 15-keto-dihydro-PGF2 , prostaglandin E2 
(PGE2), leukotriene B4 (LTB4), interferon-γ] or vascular inflammation [soluble vascular cell adhesion 
molecule-1 (sVCAM-1), soluble intercellular adhesion molecule-1 (sICAM-1), soluble E-selectin 
(sE-selectin)] not explicitly cited in previous EFSA opinions (EFSA Panel on Dietetic Products 
Nutrition and Allergies (NDA), 2010a, 2010b) in relation to this outcome (Aryaeian et al., 2009; 
Joseph et al., 2011; Mullen et al., 2007; Nugent et al., 2005; Pfeuffer et al., 2011; Sluijs et al., 2010; 
Smit et al., 2011; Turpeinen et al., 2008; Venkatramanan et al., 2010). 
The studies by Nugent et al. (2005), Mullen et al. (2007), and Pfeuffer et al. (2011) had already been 
considered in the meta-analysis by Herrmann, (2009) provided by one of the applicants (Pfeuffer et 
al., 2009 as personal communication), whereas the studies by Aryaeian et al. (2009)and Turpeinen et 
al. (2008) were performed in subjects with ongoing inflammatory diseases (rheumatoid arthritis and 
pollen allergy, respectively) under anti-inflammatory medications and are difficult to interpret in 
relation to this outcome.   
The remaining studies, which have been described in previous sections, did not report a significant 
effect of CLA on hs-CRP (Joseph et al., 2011; Sluijs et al., 2010; Smit et al., 2011; Venkatramanan et 
al., 2010), TNF-  (Joseph et al., 2011; Smit et al., 2011; Venkatramanan et al., 2010), IL-6 (Joseph et 
al., 2011; Smit et al., 2011), or markers of vascular inflammation (Smit et al., 2011).  
In previous evaluations (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2010a, 
2010b), the Panel noted that none of the studies evaluated had been designed to address the effects of 
CLA on subclinical inflammation, which also applies to the additional studies considered in this 
opinion with the exception of Smit et al. (2011), which used a cross-over design with significant 
limitations as outlined in section 3.3. Blood concentrations of 15-keto-dihydro-PGF2  were 
consistently increased and blood concentrations of TNF-  and IL-6 were generally not affected by 
CLA treatment, which is in line with the additional, more recent studies available. The effects of CLA 
on hs-CRP had been inconsistent, with significant increases or no change in hs-CRP being reported in 
different studies of similar design. In a meta-analysis presented by one of the applicants (Herrmann, 
2009), the 1:1 CLA mixture showed a significant increase in hs-CPR concentrations compared to the 
control group (six studies considered). Five of the studies were performed in subjects with a BMI 
>27 kg/m
2
. The effects of CLA on markers of endothelial inflammation (namely ICAM-1, VCAM-1) 
could not be assessed due to the small number of studies available, from which the results were, 
moreover, inconsistent. The Panel notes that four new studies reported no effect of CLA on hs-CRP, 
that three of these studies were conducted in overweight subjects (Joseph et al., 2011; Sluijs et al., 
2010; Venkatramanan et al., 2010) and that one of these had a bigger sample size than all the studies 
in the meta-analysis by Herrmann (2009) combined (n=173 per intervention group; Sluijs et al., 
2010). However, the Panel also notes that the study by Sluijs et al. (2010) used 3.1 g/day CLA of the 
80:20 c-9, t-11 and t-10,c-12 isomer mixture, in which the t-10,c-12 isomer is underrepresented with 
respect to the conditions of use proposed by the applicants and to the blends used in the studies 
considered by Herrmann (2009). Only one new study reported on markers of vascular inflammation 
(Smit et al., 2011).  
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The Panel considers that the additional information provided does not contain evidence that would 
modify the previous conclusions reached by the Panel regarding the effects of CLA on markers of 
subclinical inflammation.  
3.5. Vascular function and vascular damage 
Two additional studies have been quoted in the ANSES opinion (2011) as new evidence with respect 
to previous EFSA opinions on the effects of CLA on vascular function (Pfeuffer et al., 2011; Sluijs et 
al., 2010). The results of one of these studies, which were provided to EFSA by the applicants in 
confidence, were already described in the EFSA opinions and referenced as Pfeuffer et al. (2009, 
unpublished).  
The study by Sluijs et al. (2010) was conducted in 401 overweight or obese adults (342 analysed) 
aged 40–70 years who consumed either 3.1 g/day CLA (80:20 mixture of the c-9-t-11 and t-10-c-12 
isomers) or a control fat (a blend of 80 % palm oil and 20 % soybean oil) in capsules for six months. 
No significant effect of the intervention was reported on arterial stiffness (measured as aortic pulse 
wave velocity), which was the primary outcome of the study, or on blood pressure. 
In its previous opinions (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2010a, 
2010b), the Panel considered the effects of CLA consumption on lipid peroxidation, subclinical 
inflammation and vascular function, their association with an increased risk of cardiovascular disease, 
and concluded that adverse effects on the arterial wall resulting from these changes, if any, would be 
expected to manifest only in the long term. The Panel notes that no additional information has become 
available on the effects of CLA intake on vascular function, vascular damage or atherosclerosis in 
humans for periods longer than six months that would modify the conclusions reached by the Panel 
regarding the potential effects of CLA on vascular damage. 
3.6. Liver function and liver steatosis 
Some animal studies had reported an increased lipid accumulation in the liver of mice fed high 
concentrations of CLA. The proposed mechanisms include (i) activation of peroxisome-
proliferator-activated receptor (PPAR) regulated genes, (ii) increased plasma insulin and/or reduced 
leptin concentrations, and (iii) uptake of CLA into fat stores of the liver (EFSA Panel on Dietetic 
Products Nutrition and Allergies (NDA), 2010a, 2010b). 
Most of the intervention studies with CLA conducted in humans already evaluated by the Panel did 
not report adverse effects on liver function enzymes at the proposed conditions of use. However, 
effects of CLA consumption over periods longer than six months on liver steatosis have not been 
adequately addressed in humans.  
An additional study identified by the Panel (Wanders et al., 2010b) administered 19.3 g/day of the 
80:20 CLA isomer mixture for 3 weeks to 20 healthy subjects with a BMI < 30kg/m
2
 in replacement 
of other fatty acids in the usual diet with no clinically relevant effects on liver function enzymes. The 
Panel notes the very high dose of CLA used and the short duration of the study. The Panel also notes 
that the effects of CLA on liver function enzymes at the proposed conditions of use have already been 
found to be of no concern and that no studies are available on the effects of CLA on liver steatosis 
over periods longer than six months. 
The Panel considers that no additional information has become available which would modify the 
previous conclusion of the Panel that the effects of CLA on liver steatosis have not been adequately 
addressed in human studies.  
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DISCUSSION 
In its previous opinions (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2010a, 
2010b), the Panel considered that CLA consumption did not appear to have adverse effects on insulin 
sensitivity, blood glucose control or liver function for periods up to six months, and that the observed 
effects on blood lipids were unlikely to have an impact on CVD risk. However, the observed increase 
in plasma and urinary concentrations of isoprostanes, which may indicate an increase in lipid 
peroxidation, and the increase in some markers of subclinical inflammation (i.e., 
15-keto-dihydroprostaglandin F2  and possibly CRP) associated with CLA consumption, together with 
the limited data available on the effects of CLA on vascular function, may indicate a potential for 
vascular damage (i.e., atherosclerosis) in the long term. Long-term effects of CLA intake on insulin 
sensitivity, the arterial wall or liver steatosis had not been adequately addressed in humans. The 
evidence provided did not establish the safety of CLA consumption by type-2 diabetic subjects under 
the proposed conditions of use. 
The Panel considers that the additional information provided does not contain evidence that would 
modify the previous conclusions reached by the Panel regarding the effects of CLA on insulin 
sensitivity, blood glucose control, blood lipids, lipid peroxidation, or subclinical inflammation. The 
Panel also considers that the new studies provided do not address longer-term (> 6 months) effects of 
CLA intake on insulin sensitivity, the arterial wall or liver steatosis, or the safety of CLA in type-2 
diabetic subjects, under the proposed conditions of use.    
CONCLUSIONS  
The Panel considers that the additional information provided does not contain evidence that would 
modify the previous conclusions reached by the Panel. 
The Panel concludes that the safety of Clarinol® and Tonalin  TG 80, two oils with approximately 
80 % of the CLA 50:50 mixture of t-9,c-11 and t-10,c-12 isomers, has been established for the 
proposed uses and daily doses (3.75 g Clarinol® and 4.5 g Tonalin  TG 80 corresponding to 
approximately 3 and 3.5 g of CLA, respectively) for up to six months. The safety of CLA 
consumption for periods longer than six months has not been established under the proposed 
conditions of use. The safety of CLA consumption by type-2 diabetic subjects has not been 
established.  
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GLOSSARY AND ABBREVIATIONS 
CLA  conjugated linoleic acid 
hs-CRP  high-sensitivity C-reactive protein 
HOMA-IR homeostasis model insulin resistance index 
PWV  pulse wave velocity 
PPAR  peroxisome-proliferator-activated receptor  
sVCAM-1 soluble vascular cell adhesion molecule-1 
sICAM-1 soluble intercellular adhesion molecule-1  
sE-selectin soluble E-selectin 
TRAP  plasma total radical-trapping antioxidant potential  
